AR081032A1 - Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan - Google Patents

Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan

Info

Publication number
AR081032A1
AR081032A1 ARP110101607A ARP110101607A AR081032A1 AR 081032 A1 AR081032 A1 AR 081032A1 AR P110101607 A ARP110101607 A AR P110101607A AR P110101607 A ARP110101607 A AR P110101607A AR 081032 A1 AR081032 A1 AR 081032A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical formulation
hmg
irbesartan
coa reductase
reductase inhibitor
Prior art date
Application number
ARP110101607A
Other languages
English (en)
Inventor
Yong Il Kim
Young Jun Na
Min Jung Kim
Young-Hun Kim
Jae Hyun Park
Jong Soo Woo
Original Assignee
Hanmi Holdings Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45395310&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR081032(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Holdings Co Ltd filed Critical Hanmi Holdings Co Ltd
Publication of AR081032A1 publication Critical patent/AR081032A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steering Devices For Bicycles And Motorcycles (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se presenta una formulacion farmacéutica en forma de comprimidos de dos fases que consiste en una primera fase que contiene irbesartan o sales aceptables desde el punto de vista farmacéutico de los anteriores y una segunda fase que contiene un inhibidor de HMG-CoA reductasa y un aditivo alcalino, que puede mejorar la velocidad de disolucion y la estabilidad de irbesartan y un inhibidor de HMG-CoA reductasa para potenciar la biodisponibilidad del fármaco cuando se compara con formulaciones complejas convencionales y para minimizar la generacion de los compuestos relacionados, de este modo usándose en forma efectiva como un agente terapéutico superior y estable para hipertension y la hipercolesterolemia. Reivindicacion 2: La formulacion farmacéutica de la reivindicacion 1, en donde el inhibidor de RMG-CoA reductasa se selecciona del grupo que consiste en rosuvastatina, lovastatina, atorvastatina, pravastatina, fluvastatina, pitavastatina, simvastatina, rivastatina, cerivastatina, velostatina, mevastatina, las sales aceptables desde el punto de vista farmacéutico, precursores, y mezclas de los anteriores. Reivindicacion 6: La formulacion farmacéutica bifásica de la reivindicacion 1, en donde el aditivo alcalino se selecciona del grupo que consiste en NaHCO3, CaCO3, MgCO3, KH2PO4, K2HPO3, fosfato tribásico de calcio, arginina, lisina, histidina, meglumina, silicato de magnesio y aluminio, metasilicato de magnesio y aluminio, y sales y mezclas de los anteriores.
ARP110101607A 2010-05-14 2011-05-10 Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan AR081032A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20100045636 2010-05-14
KR1020100053782A KR101248804B1 (ko) 2010-05-14 2010-06-08 ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제

Publications (1)

Publication Number Publication Date
AR081032A1 true AR081032A1 (es) 2012-05-30

Family

ID=45395310

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101607A AR081032A1 (es) 2010-05-14 2011-05-10 Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan

Country Status (36)

Country Link
US (1) US20130028974A1 (es)
EP (1) EP2568972B1 (es)
JP (1) JP5969466B2 (es)
KR (2) KR101248804B1 (es)
CN (1) CN103002883B (es)
AR (1) AR081032A1 (es)
AU (2) AU2011251085A1 (es)
BR (1) BR112012029064B8 (es)
CA (1) CA2798363C (es)
CL (1) CL2012003185A1 (es)
CO (1) CO6592025A2 (es)
CR (1) CR20120545A (es)
DK (1) DK2568972T3 (es)
DO (1) DOP2012000264A (es)
EA (1) EA023959B1 (es)
EC (1) ECSP12012224A (es)
ES (1) ES2645726T3 (es)
GT (1) GT201200309A (es)
HK (1) HK1181685A1 (es)
HU (1) HUE036638T2 (es)
IL (1) IL223012B (es)
JO (1) JO3409B1 (es)
MA (1) MA34313B1 (es)
MX (1) MX342868B (es)
MY (1) MY157307A (es)
NI (1) NI201200170A (es)
NZ (1) NZ604402A (es)
PE (2) PE20130204A1 (es)
PL (1) PL2568972T3 (es)
PT (1) PT2568972T (es)
SG (1) SG185778A1 (es)
SI (1) SI2568972T1 (es)
TW (1) TW201200166A (es)
UA (1) UA107967C2 (es)
WO (1) WO2011142621A2 (es)
ZA (1) ZA201209481B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103356500A (zh) * 2012-03-30 2013-10-23 肖广常 一种瑞舒伐他汀钙非诺贝特酸胆碱盐择时渗透泵控释片及其制备方法
BR102012020648A2 (pt) * 2012-08-17 2014-12-09 Hypermarcas S A Preparação farmacêutica oral sólida para a prevenção de doença cardio e cerebrovasculares e comprimido
KR20140028971A (ko) * 2012-08-31 2014-03-10 한미약품 주식회사 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
KR20140030505A (ko) * 2012-08-31 2014-03-12 한미약품 주식회사 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
ES2747098T3 (es) * 2013-03-14 2020-03-10 Boryung Pharm Fármaco de combinación farmacéutica
KR101597004B1 (ko) * 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
KR20150079373A (ko) * 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
KR101771766B1 (ko) * 2013-12-30 2017-08-28 알보젠코리아 주식회사 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제
CN105769793A (zh) * 2016-04-04 2016-07-20 孙爱华 一种辛伐他汀片剂及其制备方法
KR102465736B1 (ko) * 2018-12-31 2022-11-11 주식회사 보령 정제 및 이의 제조방법
KR102042626B1 (ko) * 2019-06-26 2019-11-11 한미약품 주식회사 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
WO2022260439A1 (ko) * 2021-06-09 2022-12-15 주식회사 보령 약학적 복합 제제 및 제조 방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
JP2003073270A (ja) * 2001-08-30 2003-03-12 Nisshin Seiyaku Kk 安定性および溶出性の良好なプラバスタチンナトリウム錠
PT1467712E (pt) * 2002-01-16 2008-01-09 Boehringer Ingelheim Pharma Comprimido farmacêutico de duas camadas compreendendo telmisartan e hidroclorotiazida
PL376577A1 (pl) * 2002-06-17 2006-01-09 Themis Laboratories Private Limited Wielowarstwowe tabletki zawierające tiazolidinedion i biguanidy oraz metody ich wytwarzania
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US20060078615A1 (en) * 2004-10-12 2006-04-13 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and simvastatin
US20080131503A1 (en) * 2005-02-10 2008-06-05 Per Holm Stable Pharmaceutical Composition Comprising a Fixed Dose Combination of Fenofibrate and an Hmg-Coa Reductase Inhibitor
EP1942921A4 (en) * 2005-10-25 2011-03-09 Merck Sharp & Dohme COMBINATION OF A DIPEPTIDYL PEPTIDASE-4 INHIBITOR AND AN ANTI-HYPERTENING AGENT FOR THE TREATMENT OF DIABETES AND HYPERTENSION
WO2008010008A2 (en) * 2006-07-17 2008-01-24 Wockhardt Limited Cardiovascular combinations using rennin-angiotensin inhibitors
AU2007314795B2 (en) * 2006-10-30 2012-02-16 Hanall Biopharma Co., Ltd. Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors
WO2008068217A2 (en) * 2006-12-04 2008-06-12 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a coated hmg-coa reductase inhibitor and an inhibitor of the renin-angiotensin system
EP2281557A4 (en) * 2008-04-29 2011-08-31 Hanall Biopharma Co Ltd PHARMACEUTICAL FORMULATION CONTAINING AN ANGIOTENSIN II RECEPTOR BLOCKING AGENT
KR20090114324A (ko) * 2008-04-29 2009-11-03 한올제약주식회사 약제학적 제제
KR20090114190A (ko) * 2008-04-29 2009-11-03 한올제약주식회사 방출성이 제어된 ＨＭＧ―ＣｏＡ 환원 효소 억제제와안지오텐신―Ⅱ―수용체 차단제의 복합 조성물
CN101590231A (zh) * 2008-05-29 2009-12-02 北京奥萨医药研究中心有限公司 血管紧张素ⅱ受体拮抗剂、他汀类降脂药和烟酸的药物组合物及其用途
CZ301299B6 (cs) * 2008-11-24 2010-01-06 Zentiva, A.S. Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem

Also Published As

Publication number Publication date
NZ604402A (en) 2015-02-27
CO6592025A2 (es) 2013-01-02
IL223012A0 (en) 2013-02-03
HK1181685A1 (zh) 2013-11-15
UA107967C2 (en) 2015-03-10
KR101248804B1 (ko) 2013-03-29
NI201200170A (es) 2013-05-29
TW201200166A (en) 2012-01-01
MY157307A (en) 2016-05-31
CR20120545A (es) 2012-12-06
SI2568972T1 (sl) 2017-10-30
ECSP12012224A (es) 2012-11-30
EP2568972A4 (en) 2014-07-02
PL2568972T3 (pl) 2017-12-29
BR112012029064B8 (pt) 2020-08-11
MA34313B1 (fr) 2013-06-01
EP2568972A2 (en) 2013-03-20
IL223012B (en) 2019-03-31
WO2011142621A3 (en) 2012-03-08
CA2798363C (en) 2018-06-05
EP2568972B1 (en) 2017-08-02
PE20151905A1 (es) 2016-01-07
CN103002883B (zh) 2015-08-26
AU2011251085A1 (en) 2013-01-10
JP5969466B2 (ja) 2016-08-17
ES2645726T3 (es) 2017-12-07
DOP2012000264A (es) 2012-11-30
ZA201209481B (en) 2014-02-26
WO2011142621A2 (en) 2011-11-17
KR20110126020A (ko) 2011-11-22
CL2012003185A1 (es) 2013-02-22
AU2016203739B2 (en) 2017-11-02
CA2798363A1 (en) 2011-11-17
AU2016203739A1 (en) 2016-06-23
BR112012029064A2 (pt) 2016-08-09
PE20130204A1 (es) 2013-03-11
EA201291247A1 (ru) 2013-04-30
HUE036638T2 (hu) 2018-07-30
MX342868B (es) 2016-10-17
BR112012029064B1 (pt) 2019-10-22
EA023959B1 (ru) 2016-07-29
US20130028974A1 (en) 2013-01-31
KR20130024940A (ko) 2013-03-08
JP2013526516A (ja) 2013-06-24
DK2568972T3 (da) 2017-11-06
GT201200309A (es) 2014-03-14
PT2568972T (pt) 2017-10-09
CN103002883A (zh) 2013-03-27
MX2012013175A (es) 2013-01-17
JO3409B1 (ar) 2019-10-20
SG185778A1 (en) 2013-01-30

Similar Documents

Publication Publication Date Title
AR081032A1 (es) Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan
RU2022100434A (ru) Фармацевтические композиции, содержащие epa и сердечно-сосудистое средство, и способы их применения
AR082930A1 (es) Composiciones que comprenden una mezcla oleosa de acidos grasos, un tensioactivo y una estatina
RU2012116079A (ru) Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина и способы ее применения
JP2016517883A5 (es)
JP2015503588A5 (es)
WO2015025228A3 (en) Compositions and therapeutic methods for accelerated plaque regression
JP2007530528A5 (es)
WO2013066279A1 (en) Solid dosage forms comprising ezetimibe
AR080023A1 (es) Formulacion de complejos que comprende aspirina revestida con una barrera que contiene aditivo hidrofobo e inhibidor de la hmg-coa reductasa
RU2015111523A (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ КОМПОЗИТНЫХ КАПСУЛ, ВКЛЮЧАЮЩИХ ИРБЕСАРТАН И ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ
WO2011139256A2 (en) Stable rosuvastatin formulations
WO2009059717A3 (en) Pharmaceutical compositions containing statins and omega-3 fatty acids derivatives and their solid formulations for oral use
GB201121503D0 (en) Medicament delivery technology
JP2016515563A5 (es)
CL2015003561A1 (es) Composición farmacéutica para administración por vía oral para su uso para la prevención y/o el tratamiento de una enfermedad cardiovascular.
RU2016126852A (ru) Комбинированный фармацевтический препарат, содержащий блокатор рецептора ангиотензина-II и ингибитор ГМГ-КоА редуктазы
JP2015505550A5 (es)
WO2016165205A8 (zh) 一种新型的bcr-abl激酶抑制剂
RU2018110622A (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ И ИНГИБИТОР АПФ
JP2015509924A5 (es)
JP2006176498A5 (es)
WO2012015168A3 (ko) 로수바스타틴 또는 이의 약학적 허용염을 포함하는 약학 조성물
NZ603397A (en) Association of xanthine oxidase inhibitors and statins and use thereof
WO2012002921A1 (en) Multiple dosage forms comprising fenofibrate or fenofibric acid in combination with hmg co a reductase inhibitors such as statins

Legal Events

Date Code Title Description
FB Suspension of granting procedure